Is IN8bio, Inc. (INAB) a Buy, Sell, or Hold?
NASDAQ : INAB
IN8bio, Inc.
$1.24 USD
-$0.02 (-1.59%)
- Volume
- 34.7K
- Average Volume
- 59.47K
- Market Capitalization
- $11.89M
- P/E Ratio
- -0.33
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $2.73
- Year Low
- $1.17
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.50
Company Overview
NASDAQ
William T.
Biotechnology
Healthcare
INAB
18
US
USD
Liquidity Metrics
0.10
10.50
10.50
10.17
0.00
Sales & Valuation
-$
0.00
0.24
-0.82
-3.33
Profitability
-$4.44
-$19.44M
0.00%
0.00%
-96.39%
-72.26%
P/E Metrics
-0.33
0.00
0.00
Analyst Price Target & Rating
$4.00
$4.00
$4.00
3/5
4 Analysts
-69.00%
Financial Health Scores
-7.07
3/9
$20.5M
$26.26M
$3.48M
-$19.18M
Key Metrics (TTM)
-$7.6M
0.00
0.45
10.50
-96.39%
-76.21%
-347.12%
-121.35%
-328 days
Company Executives
| Name | Title |
|---|---|
| Lawrence S. Lamb | Executive Vice President, Co-Founder & Chief Scientific Officer |
| Tai-Wei | Co-Founder, CEO & Director |
| Kate Rochlin | President & COO |
| Patrick McCall | Chief Financial Officer & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About IN8bio, Inc. (NASDAQ:INAB) Stock
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Esta ... blished in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
2026-07-09 08:00:00
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs) NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology (JCO), one of the most prestigious oncology journals. The publication, titled: “ Intracranial injection of ex vivo expanded and activated gamma-delta T cells engineered with a MGMT-expressing lentivector in patients with primary glioblastoma ,” reports results from the first-in-human study of an autologous, genetically modified γδ T cell therapy.
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
2026-06-04 10:56:16
After losing some value lately, a hammer chart pattern has been formed for IN8bio (INAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2026-06-03 08:30:00
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “Harnessing γδ T cells through engineering and combination therapies” in the journal Nature Communications. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D.
2026-06-01 08:30:00
Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-07 16:30:00
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026 Hosting R&D Day on May 21, 2026 in New York City NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2026.
2026-05-06 08:00:00
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical and scientific conferences in May and June 2026, including new clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting. IN8bio will also host a Research and Development (R&D) Day on May 21, 2026, showcasing advances across its γδ T cell pipeline, including its novel T cell engager (TCE) and clinical γδ T cell therapy programs.
Frequently Asked Questions
-
What is the current IN8bio, Inc. (INAB) stock price?
-
IN8bio, Inc.(NASDAQ:INAB) stock price is $1.24 in the last trading session. During the trading session, INAB stock reached the peak price of $2.73 while $1.17 was the lowest point it dropped to. The percentage change in INAB stock occurred in the recent session was --1.59% while the dollar amount for the price change in INAB stock was -$0.02.
-
INAB's industry and sector of operation?
-
The NASDAQ listed INAB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INAB?
-
Lawrence S. Lamb | Executive Vice President, Co-Founder & Chief Scientific Officer
Tai-Wei | Co-Founder, CEO & Director
Kate Rochlin | President & COO
Patrick McCall | Chief Financial Officer & Secretary
| -
How many employees does INAB have?
-
Number of INAB employees currently stands at 18. INAB operates from 350 5th Avenue, New York City, NY 10118, US.
-
Link for INAB official website?
-
Official Website of INAB is: https://in8bio.com
-
How do I contact INAB?
-
INAB could be contacted at phone #646 600 6438 and can also be accessed through its website. INAB operates from 350 5th Avenue, New York City, NY 10118, US.
-
How many shares of INAB are traded daily?
-
The average number of INAB shares traded daily for last 3 months was 59.47K.
-
What is the market cap of INAB currently?
-
The market value of INAB currently stands at $11.89M with its latest stock price at $1.24